The 4R-tauopathies—including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), globular glial tauopathy (GGT), and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17)—share a common pathological feature: the accumulation of hyperphosphorylated 4-repeat tau in oligodendrocytes and subsequent white matter degeneration. While each disease has distinct clinical phenotypes, the myelin pathology reveals both shared mechanisms and disease-specific patterns that inform diagnosis and therapeutic development.
This page provides a comprehensive cross-disease comparison of myelin and white matter dysfunction in 4R-tauopathies, synthesizing current understanding of oligodendrocyte tau inclusions, white matter degeneration patterns, myelin protein alterations, remyelination failure, and therapeutic implications.
| Feature | PSP | CBD | AGD | GGT | FTDP-17 |
|---|---|---|---|---|---|
| Primary Oligodendrocyte Inclusion | Coiled bodies | Coiled bodies, globoid | threads | Globular oligodendroglial inclusions (GOIs) | Variable |
| Tau Isoform | 4R | 4R | 4R | 4R | 4R (mutation-dependent) |
| Regional Distribution | Symmetric, brainstem-predominant | Asymmetric, cortical/subcortical | Limbic-predominant | White matter-predominant, multi-focal | Variable by mutation |
| White Matter Severity | Moderate-severe | Severe | Mild-moderate | Severe | Moderate |
| MBP Alteration | Reduced, proteolytic cleavage | Reduced | Mild reduction | Severe reduction | Variable |
| CNPase Loss | Moderate | Significant | Mild | Severe | Variable |
| Iron Association | Prominent in GP/STN | Variable | Present | Prominent | Variable |
| Clinical Correlation | Gait, oculomotor | Asymmetric rigidity, apraxia | Memory/behavior | Variable, often PSP-like | Early parkinsonism/dementia |
MBP = myelin basic protein; CNPase = 2',3'-cyclic nucleotide 3'-phosphodiesterase; GP = globus pallidus; STN = subthalamic nucleus
PSP demonstrates the prototypical oligodendroglial tau pathology characterized by coiled bodies— filamentous inclusions in the perinuclear cytoplasm of oligodendrocytes[1]. These inclusions are composed of hyperphosphorylated 4R tau that aggregates into paired helical filaments. The distribution follows a characteristic pattern:
Oligodendroglial tau in PSP appears early in disease progression and often precedes significant neuronal loss, suggesting a primary role in white matter degeneration[2].
CBD shows more severe oligodendrocyte pathology than PSP, with both coiled bodies and globoid inclusions that are morphologically distinct[3][4]. Key features include:
The regional distribution is notably asymmetric, reflecting the clinical asymmetry of CBS. Oligodendrocyte pathology correlates with the severity of cortical and subcortical involvement.
AGD shows oligodendroglial tau primarily in the form of argyrophilic grains and pretangles in white matter[5]. The pattern differs from PSP and CBD:
White matter involvement in AGD is generally less severe than PSP or CBD, correlating with the more indolent clinical course[6].
GGT represents the most severe oligodendrocyte pathology among 4R-tauopathies, with characteristic globular oligodendroglial inclusions (GOIs)[7]. These are:
GGT shows prominent white matter involvement with early and severe demyelination. The name "globular glial" reflects both the globular oligodendroglial and astroglial inclusions that define this entity.
FTDP-17 shows variable oligodendrocyte pathology depending on the specific MAPT mutation:
White matter changes in MAPT mutation carriers can precede clinical symptoms, with DTI showing reduced fractional anisotropy in mutation carriers even before symptom onset[8].
| Disease | Typical MRI Findings | DTI Changes |
|---|---|---|
| PSP | Midbrain atrophy, "hummingbird" sign, callosal thinning | FA↓ in corpus callosum, internal capsule, corticospinal tracts |
| CBD | Asymmetric cortical/subcortical atrophy, callosal atrophy | FA↓ asymmetrically, MD↑ in affected regions |
| AGD | Hippocampal atrophy, mild white matter changes | Minimal DTI changes, predominantly limbic |
| GGT | Diffuse white matter atrophy, focal T2 hyperintensities | Severe FA reduction throughout white matter |
| FTDP-17 | Variable by mutation, often frontal atrophy | FA↓ correlating with mutation severity |
The pattern of white matter involvement follows disease-specific gradients:
PSP: Basal ganglia white matter > brainstem tracts > corpus callosum > periventricular > cortical U-fibers
CBD: Cortical/subcortical white matter (asymmetric) > corpus callosum > brainstem
AGD: Limbic white matter > temporal white matter > frontal > other regions
GGT: Diffuse, multi-focal white matter involvement with regional variation
MBP is the major protein component of myelin and is consistently affected across 4R-tauopathies:
The cleavage of MBP by calcium-activated proteases represents a final common pathway for myelin breakdown across 4R-tauopathies[10].
PLP is the most abundant myelin protein and shows:
CNPase is a marker of oligodendrocyte viability:
MAG is an early marker of myelin damage:
OPCs are present in 4R-tauopathies but fail to mature into myelinating oligodendrocytes:
| Factor | Effect in 4R-Tauopathies | Therapeutic Target |
|---|---|---|
| PDGF signaling | Reduced | PDGF agonists |
| NG2 expression | Altered | NG2 modulators |
| SOX10 | Dysregulated | Transcription factor enhancers |
| Tau pathology | OPCs may accumulate tau | Tau reduction |
| Inflammation | Inhibits differentiation | Anti-inflammatory |
The failure of OPC maturation represents a critical therapeutic target[11]. Multiple factors contribute:
The remyelination cascade is interrupted at multiple points:
Iron dysregulation is a common feature:
Microglial activation drives myelin pathology:
Tau spreads between cells via multiple mechanisms[12]:
This propagation explains the spreading pattern of white matter pathology within affected tracts.
Oligodendrocytes provide metabolic support to axons via lactate shuttle (MCT1):
This page integrates with existing NeuroWiki mechanism pages:
This page specifically focuses on:
Tau-Targeted Therapies:
Myelin-Protective Strategies:
Iron Chelation:
| Approach | Target | Stage | Potential Benefit |
|---|---|---|---|
| Anti-LINGO-1 | OPC maturation | Phase 2 (MS) | May promote remyelination |
| PDGF agonists | OPC proliferation | Preclinical | Increase OPC numbers |
| S1P modulators | Oligodendrocyte survival | Approved (MS) | Protect existing myelin |
| GSK-3 inhibitors | Tau phosphorylation | Phase 1 | Reduce tau in OLs |
| NAD+ precursors | Oligodendrocyte metabolism | Phase 2 | Support energy needs |
| Biomarker | Source | Disease | Utility |
|---|---|---|---|
| MBP | CSF | All 4R-tauopathies | Demyelination marker |
| Neurofilament light chain (NfL) | CSF, blood | All 4R-tauopathies | Axonal damage, correlates with myelin loss |
| Myelin water fraction | MRI | All 4R-tauopathies | Direct myelin measurement |
| DTI (FA/MD) | MRI | All 4R-tauopathies | White matter integrity |
| Choline | MRS | All 4R-tauopathies | Membrane turnover, elevated in demyelination |
Primary oligodendrocyte pathology: All 5 diseases show primary oligodendrocyte tau inclusions that drive myelin breakdown, not merely secondary to neuronal loss
Disease-specific patterns: Regional distribution, inclusion morphology, and severity differ meaningfully between diseases—useful for differential diagnosis
Shared mechanisms: Iron accumulation, neuroinflammation, metabolic failure, and tau propagation represent common therapeutic targets
MBP proteolysis: Calpain-mediated MBP cleavage is a final common pathway across 4R-tauopathies
Remyelination failure: OPCs are present but fail to mature due to tau pathology, inflammation, and growth factor deficiency
Therapeutic window: Protecting existing myelin and promoting remyelination could slow disease progression across the 4R-tauopathy spectrum
Dickson DW, et al. Neuropathology of PSP. Acta Neuropathol. 2020. ↩︎
Kompoliti K, et al. Oligodendroglial tau in PSP. Arch Neurol. 1998. ↩︎
Marquez G, et al. Oligodendrocyte pathology in corticobasal syndrome: A comparative study. Acta Neuropathol Commun. 2023. ↩︎ ↩︎
Ling H, et al. Oligodendroglial pathology in CBD. Acta Neuropathol. 2014. ↩︎
Arai T, et al. Argyrophilic grain disease: neuropathological features and updated diagnostic criteria. Acta Neuropathol. 2019. ↩︎
Thompson A, et al. White matter involvement in argyrophilic grain disease. Acta Neuropathol. 2018. ↩︎
Ahmed Z, et al. Globular glial tauopathy: a novel 4R tauopathy. Acta Neuropathol. 2013. ↩︎
Dopper EG, et al. White matter integrity in MAPT mutation carriers. Neurobiol Aging. 2016. ↩︎
Ahmadi M, et al. Calpain activation in PSP white matter. Neurobiol Aging. 2020. ↩︎
Wenner M, et al. MBP cleavage in 4R tauopathies: mechanism and therapeutic implications. Brain. 2023. ↩︎
Bjorklund LM, et al. Remyelination in 4R tauopathies. Nat Rev Neurol. 2018. ↩︎
Chen W, et al. Tau propagation in oligodendrocytes. Nat Neurosci. 2024. ↩︎